Open AccessACTUALIZED INFORMATION ON THE USE OF LEVOCETIRIZINE IN URTICARIA
Author(s) -
N. Astafieva,
Denis Kobzev,
I. Gamova,
I. Perfilova,
Е. Н. Удовиченко,
I E Mikhaylova,
L V Skuchaeva
Publication year - 2017
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja284
Subject(s) - levocetirizine , cetirizine , medicine , disease , clinical trial , intensive care medicine , pharmacology
Urticaria is a widespread disease with various phenotypes, duration and severity of the course, a pronounced effect on the quality of life. Despite the heterogeneity of the disease, a huge variety of provoking triggers, the activation of mast cells is still considered the key link in pathogenesis, and therefore antihistamines of the 2nd generation remain effective and safe drugs for treatment of urticaria. The process of improving antihistamines actively continues, one of the directions is the search for molecules based on the release of more active and safe enantiomers from already known drugs (example: levocetirizine from cetirizine). Information on levocetirizine, the efficacy and safety of which in the treatment of urticaria in both adults and children, has been demonstrated in a number of well-planned randomized controlled clinical trials, as well as in various preclinical studies, due to the accumulation of new data, the advent of generic drugs, and also a new scale for assessing the quality of clinical data in the GRADE system needs to be updated. The present review is devoted to solving this problem.